Your browser doesn't support javascript.
loading
Antisense MicroRNA Therapeutics in Cardiovascular Disease: Quo Vadis?
Philippen, Leonne E; Dirkx, Ellen; Wit, Jan B M; Burggraaf, Koos; de Windt, Leon J; da Costa Martins, Paula A.
Afiliación
  • Philippen LE; Department of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
  • Dirkx E; Department of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
  • Wit JB; Cristal Therapeutics BV, Maastricht, The Netherlands.
  • Burggraaf K; Center for Human Drug Research, Leiden University Medical Center, Leiden, The Netherlands.
  • de Windt LJ; Department of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
  • da Costa Martins PA; Department of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
Mol Ther ; 23(12): 1810-8, 2015 Dec.
Article en En | MEDLINE | ID: mdl-26216517
ABSTRACT
Heart failure (HF) is the end result of a diverse set of causes such as genetic cardiomyopathies, coronary artery disease, and hypertension and represents the primary cause of hospitalization in Europe. This serious clinical disorder is mostly associated with pathological remodeling of the myocardium, pump failure, and sudden death. While the survival of HF patients can be prolonged with conventional pharmacological therapies, the prognosis remains poor. New therapeutic modalities are thus needed that will target the underlying causes and not only the symptoms of the disease. Under chronic cardiac stress, small noncoding RNAs, in particular microRNAs, act as critical regulators of cardiac tissue remodeling and represent a new class of therapeutic targets in patients suffering from HF. Here, we focus on the potential use of microRNA inhibitors as a new treatment paradigm for HF.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Elementos sin Sentido (Genética) / MicroARNs / Insuficiencia Cardíaca Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Mol Ther Asunto de la revista: BIOLOGIA MOLECULAR / TERAPEUTICA Año: 2015 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Elementos sin Sentido (Genética) / MicroARNs / Insuficiencia Cardíaca Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Mol Ther Asunto de la revista: BIOLOGIA MOLECULAR / TERAPEUTICA Año: 2015 Tipo del documento: Article País de afiliación: Países Bajos